Cannabis Science Inc (fka CBIS)

[oystersnbeer]

COLORADO SPRINGS, Colo., Nov. 21, 2013 /PRNewswire via COMTEX/ -- Cannabis
Science, Inc., (NASDAQ OTC: CBIS) a U.S. Company specializing in cannabis
formulation-based drug development, announces the signing of a broad licensing
agreement with strategic partner Endocan Corporation (NASDAQ OTC: ENDO) to use
patent N2010968, entitled "Composition for the Treatment of Neurobehavioral
Disorders", for Endocan studies, research and development, and consumer
products.

As previously announced, the subject of the patent is development of
cannabinoid-based formulations to treat a variety of widespread neurobehavioral
conditions, such as attention deficit hyperactivity disorder (ADHD), anxiety,
and sleep disorders. The products that Endocan intends to produce using the
patent will target substantial international markets that should prove to help
many people in need worldwide. At the same time, Cannabis Science will be moving
forward with research and clinical development of pharmaceutical grade drugs via
the patent.

"We are very excited with the quick movement in reaching a mutually-beneficial
agreement with Endocan Corporation regarding the use of our recently filed
patent addressing cannabinoid-based treatment for various neurobehavioral
disorders. Both of these companies have different but synergistic missions and
can together take this intellectual property to the market at multiple levels,"
stated Dr. Dorothy Bray, CEO and Director, Cannabis Science, Inc.

Cannabis Science's IP strategy includes developing, owning, and licensing
patents for the Company's proprietary drug development operations and
collaborations with other industry actors to most effectively help patients.

About Cannabis Science, Inc.

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic
processes to provide novel treatment approaches to a number of illnesses for
which current treatments and understanding remain unsatisfactory. Cannabinoids
have an extensive history dating back thousands of years, and currently there
are a growing number of peer-reviewed scientific publications that document the
underlying biochemical pathways that cannabinoids modulate. The Company works
with leading experts in drug development, medicinal characterization, and
clinical research to develop, produce, and commercialize novel therapeutic
approaches for the treatment for illnesses caused by infections as well as for
age-related illness. Our initial focus is on skin cancers and HIV related
cancers such as Kaposi's sarcoma.